Biocon: In US, we are now competing with Big Pharma – Times of India
BENGALURU: The decision by the US FDA to label Biocon’s insulin glargine as an interchangeable biosimilar is a momentous decision...
BENGALURU: The decision by the US FDA to label Biocon’s insulin glargine as an interchangeable biosimilar is a momentous decision...
WASHINGTON: The ongoing Covid-19 public health crisis has resulted in the creation of an "ecosystem" of innovation in India, Biocon...
NEW DELHI: Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make...